| Filed On | Filing |
|---|---|
| 29 Sep 2026 |
8-K: Other Events
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance |
| 07 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 06 Aug 2026 | FORM 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Jul 2026 | 8-K: Other Events |
| 21 Jul 2026 | SCHEDULE 13G/A |
| 02 Jul 2026 |
Form 4: Waldman Lawrence, Director
Received 12,000 shares by exercise or conversion ($22.6K) · Gave up 5,024 shares to cover exercise price or tax ($22.6K) |
| 26 Jun 2026 |
Proxy statement: annual meeting on August 6, 2026
CEO pay $1.2M, up 26% · say-on-pay vote |
| 17 Jun 2026 |
Form 4: Roman Shawn David, Chief Operating Officer
Received 15,000 shares by exercise or conversion ($48.5K) · Gave up 10,533 shares to cover exercise price or tax ($48.5K) |
| 17 Jun 2026 | 8-K: Entry into a Material Definitive Agreement |
| 15 Jun 2026 |
Form 4: Levine Wendy Lauren, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Vizirgianakis Stavros G., Director
Received 450,000 shares as a grant or award |
| 15 Jun 2026 |
Form 4: Goodwin Charles D. Ii, Director
Granted 213,948 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Roman Shawn David, Chief Operating Officer
Granted 88,044 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Baylor-Henry Minnie, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Waldman Lawrence, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Hill Matthew C, Chief Financial Officer
Granted 132,066 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Citronowicz Moshe, Sr. V.P. of Operations
Granted 63,392 Stock Option (Option to Buy) |
| 01 Jun 2026 | FORM SD |
| 21 May 2026 | 8-K: Other Events |
Loading...
